582303-10-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Pyridinemethanol,2,6-dimethyl-(9CI) is utilized as a key building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable component in the development of new drugs and pesticides, contributing to advancements in healthcare and agriculture.
Used in Organic Chemistry Research:
As a derivative of pyridine, 3-Pyridinemethanol,2,6-dimethyl-(9CI) is employed as a solvent, reagent, or intermediate in a wide range of chemical processes and reactions. Its versatility and reactivity enable researchers to explore new synthetic pathways and develop innovative organic compounds.
Used in Antimicrobial and Antifungal Applications:
3-Pyridinemethanol,2,6-dimethyl-(9CI) has been studied for its potential biological activities, including antimicrobial and antifungal properties. Its ability to inhibit the growth of certain microorganisms makes it a promising candidate for use in antimicrobial and antifungal agents, offering potential applications in healthcare and sanitation.
Overall, 3-Pyridinemethanol,2,6-dimethyl-(9CI) is a multifaceted compound with diverse applications across various industries, including pharmaceuticals, agrochemicals, organic chemistry research, and antimicrobial and antifungal applications. Its unique structure and properties make it an essential component in the development of new compounds and contribute to the advancement of scientific knowledge and practical applications.

Upstream product

• 1721-13-7 ethyl 2,6-dimethylnicotinate 
• 70271-80-6 ethyl 4-chloro-2,6-dimethylnicotinate 

Downstream Products

• 650141-20-1 2,6-dimethylpyridine-3-carboxaldehyde 
• 672325-49-4 (2,6-dimethylpyridin-3-yl)methanamine 
• 1462-84-6 2,3,6-trimethylpyridine 
• 118420-52-3 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(2,6-dimethyl-pyridin-3-yl)-acrylamide 

Relevant academic research and scientific papers

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Alpha-substituted arylalkyl phosphonate derivatives

The present invention relates to novel α-substituted arylalkylphosphonate derivatives and their uses for lowering plasma levels of apo (a), Lp(a), apo B, apo B associated lipoproteins (low density lipoproteins and very low density lipoproteins) and for lo

Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compounds 1a [(E)-N-[4 [4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, 4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.